Takayuki Tokunaga

Kumamoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Comparison of RATS Lobectomy and VATS Lobectomy for Early-stage Non-small Cell Lung Cancer.

Comparison of RATS Lobectomy and VATS Lobectomy for Early-stage Non-small Cell Lung Cancer.

Journal: Anticancer research

Published: March 29, 2026

Mendelian Randomization Using a Japanese GWAS Identifies an HLA-Linked Causal Effect of Chronic Hepatitis B on Cholangiocarcinoma Risk.

Mendelian Randomization Using a Japanese GWAS Identifies an HLA-Linked Causal Effect of Chronic Hepatitis B on Cholangiocarcinoma Risk.

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: December 02, 2025

The Prognostic Impact of C-Reactive Protein-Albumin-Lymphocyte Index (Cally Index) in Patients with Surgically Resected Non-Small-Cell Lung Cancer.

The Prognostic Impact of C-Reactive Protein-Albumin-Lymphocyte Index (Cally Index) in Patients with Surgically Resected Non-Small-Cell Lung Cancer.

Journal: Annals of surgical oncology

Published: June 20, 2025

Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 07, 2025

Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis.

Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 23, 2024

Transileocolic Portal Vein Embolization Increases Remnant Liver Volume After Major Hepatectomy.

Transileocolic Portal Vein Embolization Increases Remnant Liver Volume After Major Hepatectomy.

Journal: In vivo (Athens, Greece)

Published: July 02, 2024

Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.

Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.

Journal: Journal of gastroenterology and hepatology

Published: March 06, 2024

Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.

Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.

Journal: Cancer medicine

Published: November 03, 2023

Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.

Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 16, 2023

Stent Graft of Pseudoaneurysm Rupture After Subtotal Stomach-preserving Pancreaticoduodenectomy.

Stent Graft of Pseudoaneurysm Rupture After Subtotal Stomach-preserving Pancreaticoduodenectomy.

Journal: Anticancer research

Published: May 22, 2023

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.

Journal: Cancers

Published: January 07, 2023

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Journal: Targeted oncology

Published: September 19, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026